Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 5.7 USD -0.87% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Recursion Pharmaceuticals Inc?
Write Note

Recursion Pharmaceuticals Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Recursion Pharmaceuticals Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Gross Profit
$2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Recursion Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2021-04-16. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.

RXRX Intrinsic Value
3.26 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Recursion Pharmaceuticals Inc's Gross Profit?
Gross Profit
2m USD

Based on the financial report for Dec 31, 2023, Recursion Pharmaceuticals Inc's Gross Profit amounts to 2m USD.

Back to Top